ACRS — Aclaris Therapeutics Share News
0.000.00%
- $628.49m
- $523.07m
- $7.83m
U.S. STOCKS ON THE MOVE-Netflix, Wabtec, Chesapeake Energy
U.S. STOCKS ON THE MOVE-American Airlines, Oil companies, Salesforce
Aclaris down as BTIG downgrades to 'neutral' on dermatitis drug trial setback
U.S. STOCKS ON THE MOVE-Virgin Galactic, Meta Platforms, EchoStar
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Masimo, Tigo Energy
Aclaris falls after mid-stage trial setback for dermatitis drug
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Home Depot, SMART Global
Brief: Aclaris Therapeutics Announces Top-Line Results From 4-Week Phase 2B Trial Of ATI-1777 For Mild To Severe Atopic Dermatitis
Aclaris falls after mid-stage trial setback for dermatitis drug
U.S. STOCKS ON THE MOVE-Coinbase Global, Spirit AeroSystems, Crown Castle
Aclaris Therapeutics falls after delay on skin disease drug data
Brief: Aclaris Therapeutics Announced A Reduction Of Its Workforce By Approximately 46%
Brief: Aclaris Therapeutics Provides Corporate Update
U.S. STOCKS ON THE MOVE-Vera Bradley, Shake Shack, 2seventy Bio
U.S. STOCKS ON THE MOVE-Citigroup, Regeneron, Ormat
U.S. STOCKS ON THE MOVE-Coya, AeroVironment, Cleveland-Cliffs
U.S. STOCKS ON THE MOVE-Nio, Aclaris, Nvidia
Aclaris surges after patent agreement with Sun Pharma
Brief: Aclaris Therapeutics Announces Patent License Agreement With Sun Pharma For Alopecia